Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04518475 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults

StatusRecruiting
PhasePhase 4
Started2020-08-10
View on ClinicalTrials.gov ↗

Amendment history

2026-04-24
Study Identification, Study Status, Sponsor/Collaborators v1
Primary completion date2022-02-10→2029-02-10
Completion date2022-08-10→2030-08-10
Collaborators5 entries, revised
Affiliated Hospital of Nantong University
2020-08-15
Original filing
This multicenter randomized, open-label study aimed to compare the efficacy and safety of eltrombopag combining rituximab with eltrombopag in China adult ITP patients .This study was be conducted in adult ITP patients who had not responded to or had relapsed after previous treatment of ITP, including first line therapy and /or splenectomy.
Trial Details
NCT Number NCT04518475
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Collaborators: The Second Affiliated Hospital of Kunming Medical University, Henan Cancer Hospital, Tianjin Medical University Second Hospital, The First Affiliated Hospital of Xiamen University, Affiliated Hospital of Nantong University
Conditions Primary Immune Thrombocytopenia (ITP)
Enrollment 224 participants
Start Date 2020-08-10
Primary Completion 2029-02-10 (estimated)
Study Completion 2030-08-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-29